애디슨병 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 약제 클래스별, 유통 채널별, 지역별 및 경쟁(2021-2031년)

The Global Addison's Disease Market is anticipated to grow from USD 546.23 Million in 2025 to USD 809.68 Million by 2031, achieving a Compound Annual Growth Rate (CAGR) of 6.78%. This market primarily encompasses pharmaceutical treatments, specifically corticosteroid replacement therapies like hydrocortisone and fludrocortisone, which are crucial for managing primary adrenal insufficiency. Market expansion is fundamentally propelled by the increasing global incidence of autoimmune disorders, which necessitate lifelong hormone management for affected individuals. Furthermore, improvements in diagnostic screening infrastructure are leading to enhanced detection rates in previously underserved areas. This effectively broadens the identified patient population, which is essential for ongoing market development and sustained growth. However, a significant barrier to this expansion is the high frequency of misdiagnosis coupled with the condition's inherent rarity, which collectively diminishes commercial incentives for the creation of innovative drug delivery systems. The low disease prevalence, estimated at approximately 1 in 10,000 individuals in 2024 by the Addison's Disease Self-Help Group, fragments the market, often delaying crucial therapeutic interventions and complicating the return on investment for advanced pharmaceutical formulations.

Market Driver

A key catalyst for market growth is the ongoing development of novel modified-release and long-acting hormone therapies. These advanced formulations are designed to emulate the body's natural circadian cortisol rhythm, thereby enhancing patient compliance and clinical outcomes in primary adrenal insufficiency management, moving beyond the physiological limitations of standard immediate-release corticosteroids. The commercial success of such tailored treatments is evident, with Eton Pharmaceuticals reporting a 40% increase in third-quarter product sales to $9.8 million in November 2024, largely driven by demand for Alkindi Sprinkle, a specialized hydrocortisone replacement therapy. This underscores a market shift towards precise delivery systems, particularly benefiting vulnerable populations like pediatric patients. Additionally, increasing R&D investment in rare endocrine disease therapeutics is expanding the treatment pipeline, supported by robust clinical validation, such as Neurocrine Biosciences' positive Phase 2 CHAMPAIN study data for Efmody in May 2024 for adults with primary adrenal insufficiency. Despite these innovations, the market's niche nature, characterized by an annual incidence of roughly 0.6 per 100,000 individuals as per NIH in March 2024, necessitates a specialized development approach.

Market Challenge

The primary obstacle hindering the growth of the Global Addison's Disease Market stems from the combined effect of high misdiagnosis rates and the condition's inherent rarity. Non-specific symptoms such as fatigue and weight loss frequently cause healthcare professionals to overlook adrenal insufficiency, leading to substantial delays in diagnosis. This diagnostic lag significantly reduces the actively addressable market, as many patients remain undiagnosed and untreated, thereby diminishing the immediate demand for corticosteroid therapies. Furthermore, the scarcity of the condition leads to a fragmented commercial landscape, which lessens the financial incentive for pharmaceutical companies to invest in developing new drug formulations. The substantial costs associated with R&D become difficult to justify for an exceptionally small target demographic, preventing the achievement of economies of scale. With an estimated prevalence of approximately 1 in 100,000 individuals in the United States in 2024, according to the National Organization for Rare Disorders, securing a viable return on investment becomes challenging, which directly impedes the introduction of advanced treatment options and slows overall market expansion.

Market Trends

Two significant trends are currently reshaping the management of Addison's disease. Firstly, the advent of novel emergency hydrocortisone auto-injectors is transforming how adrenal crises-a life-threatening complication-are managed. These devices offer simplified, often needle-free, delivery mechanisms, ensuring rapid and accurate administration of rescue medication, thereby enhancing acute care safety beyond conventional vial-and-syringe methods. Commercial progress is accelerating, exemplified by Crossject's collaboration with Eton Pharmaceuticals in March 2025 to finalize the ZENEO Hydrocortisone auto-injector. Secondly, the sector is pioneering advancements in regenerative medicine, specifically through bioprinted tissue therapeutics. This innovative approach aims for a functional cure by implanting bioengineered tissues capable of restoring natural adrenal function and mimicking the body's physiological circadian cortisol rhythm, potentially eliminating the need for lifelong oral steroid replacement. Preclinical validations, such as Aspect Biosystems' July 2025 data demonstrating sustained adrenal hormone function in animal models for over six months, underscore the disruptive potential of these solutions for standard care models.

Key Market Players

• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Sanofi S.A.
• GlaxoSmithKline plc
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH

Report Scope

In this report, the Global Addison's Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Addison's Disease Market, By Type

• Primary Adrenal Insufficiency
• Secondary Adrenal Insufficiency
• Tertiary Adrenal Insufficiency

Addison's Disease Market, By Drug Class

• Oral Corticosteroid
• Corticosteroid Injections
• Sodium Intake

Addison's Disease Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Addison's Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Addison's Disease Market.

Available Customizations:

Global Addison's Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Addison's Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency, Tertiary Adrenal Insufficiency)
  • 5.2.2. By Drug Class (Oral Corticosteroid, Corticosteroid Injections, Sodium Intake)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Addison's Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Addison's Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Addison's Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Addison's Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel

7. Europe Addison's Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Addison's Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Addison's Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Addison's Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Addison's Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Addison's Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Addison's Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Addison's Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Addison's Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Addison's Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Addison's Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Addison's Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Addison's Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Addison's Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Addison's Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Addison's Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel

10. South America Addison's Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Addison's Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Addison's Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Addison's Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Addison's Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Novartis AG
• 15.4. Bristol-Myers Squibb Company
• 15.5. Eli Lilly and Company
• 15.6. Sanofi S.A.
• 15.7. GlaxoSmithKline plc
• 15.8. AbbVie Inc.
• 15.9. Takeda Pharmaceutical Company Limited
• 15.10. Boehringer Ingelheim International GmbH

16. Strategic Recommendations

17. About Us & Disclaimer